|
MXPA02011625A
(es)
|
2000-05-26 |
2003-03-27 |
Schering Corp |
Antagonistas receptores de adenosina a2a.
|
|
GB0100624D0
(en)
*
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
|
KR20040066788A
(ko)
|
2001-08-31 |
2004-07-27 |
더 락커펠러 유니버시티 |
프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1b 매개되는 신호의 조절
|
|
CA2430328A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Receptor antagonist
|
|
US6653315B2
(en)
*
|
2001-10-15 |
2003-11-25 |
Schering Corporation |
Adenosine A2a receptor antagonists
|
|
KR20050044593A
(ko)
|
2001-11-30 |
2005-05-12 |
쉐링 코포레이션 |
아데노신 A2a 수용체 길항제
|
|
PE20030739A1
(es)
|
2001-11-30 |
2003-08-28 |
Schering Corp |
Antagonistas del receptor de adenosina a2a
|
|
KR20050044600A
(ko)
|
2001-11-30 |
2005-05-12 |
쉐링 코포레이션 |
[1,2,4]-트리아졸 바이사이클릭 아데노신 A2a 수용체길항제
|
|
CA2522813C
(en)
|
2003-04-23 |
2009-09-08 |
Schering Corporation |
2-alkynyl-and 2-alkenyl-pyrazolo-¬4,3-e|-1,2,4-triazolo-¬1,5-c|-pyrimidine adenosine a2a receptor antagonists
|
|
NZ550591A
(en)
|
2004-04-21 |
2010-10-29 |
Schering Corp |
Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists
|
|
CN101248050B
(zh)
|
2005-06-06 |
2013-07-17 |
武田药品工业株式会社 |
有机化合物
|
|
CN101312978A
(zh)
|
2005-09-19 |
2008-11-26 |
先灵公司 |
作为腺苷A2a受体拮抗剂的2-杂芳基-吡唑并-[4,3-e]-1,2,4-三唑并-[1,5-c]-嘧啶
|
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
MX2008015489A
(es)
|
2006-06-06 |
2009-01-13 |
Intra Cellular Therapies Inc |
Compuestos organicos.
|
|
US9198924B2
(en)
|
2006-11-13 |
2015-12-01 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US9006258B2
(en)
|
2006-12-05 |
2015-04-14 |
Intra-Cellular Therapies, Inc. |
Method of treating female sexual dysfunction with a PDE1 inhibitor
|
|
US7691869B2
(en)
|
2007-03-30 |
2010-04-06 |
King Pharmaceuticals Research And Development, Inc. |
Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
|
|
CA2707218A1
(en)
|
2007-12-06 |
2009-06-11 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
CN104370918A
(zh)
|
2007-12-06 |
2015-02-25 |
武田药品工业株式会社 |
有机化合物
|
|
US8222259B2
(en)
|
2008-03-04 |
2012-07-17 |
Schering Corporation |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
|
|
JP2011528363A
(ja)
*
|
2008-07-16 |
2011-11-17 |
キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド |
アテローム性動脈硬化症の治療
|
|
MX2011005934A
(es)
|
2008-12-06 |
2011-12-16 |
Intra Cellular Therapies Inc |
Compuestos organicos.
|
|
ES2580759T3
(es)
|
2008-12-06 |
2016-08-26 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
|
EP2358723B1
(en)
|
2008-12-06 |
2015-05-13 |
Intra-Cellular Therapies, Inc. |
4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
|
|
CA2740398A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
PE20110922A1
(es)
|
2008-12-06 |
2012-01-22 |
Intra Cellular Therapies Inc |
DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
|
|
PE20110995A1
(es)
|
2008-12-06 |
2012-02-06 |
Intra Cellular Therapies Inc |
DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
|
|
JP2012518685A
(ja)
|
2009-02-25 |
2012-08-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
眼障害のためのpde1阻害剤
|
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2011016861A2
(en)
|
2009-08-05 |
2011-02-10 |
Intra-Cellular Therapies, Inc. |
Novel regulatory proteins and inhibitors
|
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
|
EP2576551A4
(en)
|
2010-05-31 |
2014-04-16 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
US9371327B2
(en)
|
2010-05-31 |
2016-06-21 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitor compounds
|
|
EP2575817A4
(en)
|
2010-05-31 |
2014-01-08 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
WO2012171016A1
(en)
|
2011-06-10 |
2012-12-13 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
JP6549040B2
(ja)
|
2013-02-17 |
2019-07-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
|
CA2906640C
(en)
|
2013-03-15 |
2021-07-20 |
Intra-Cellular Therapies, Inc. |
Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
|
|
EP2968338B1
(en)
|
2013-03-15 |
2019-01-09 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
|
|
WO2015106032A1
(en)
|
2014-01-08 |
2015-07-16 |
Intra-Cellular Therapies, Inc. |
Products and pharmaceutical compositions
|
|
WO2015196186A1
(en)
|
2014-06-20 |
2015-12-23 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
ES2745819T3
(es)
|
2014-08-07 |
2020-03-03 |
Intra Cellular Therapies Inc |
Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
|
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
|
IL292225B2
(en)
|
2014-09-17 |
2024-12-01 |
Intra Cellular Therapies Inc |
Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them.
|
|
RU2727805C2
(ru)
|
2014-11-18 |
2020-07-24 |
Мерк Шарп И Доум Корп. |
Аминопиразиновые соединения со свойствами антагониста a2a
|
|
CN107205999B
(zh)
|
2014-12-06 |
2021-08-03 |
细胞内治疗公司 |
有机化合物
|
|
RU2702732C1
(ru)
|
2014-12-06 |
2019-10-10 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
|
WO2016126570A1
(en)
|
2015-02-06 |
2016-08-11 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
|
EP3307067B1
(en)
|
2015-06-11 |
2022-11-02 |
Merck Sharp & Dohme LLC |
Aminopyrazine compounds with a2a antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
WO2017172795A1
(en)
|
2016-03-28 |
2017-10-05 |
Intra-Cellular Therapies, Inc. |
Novel compositions and methods
|
|
US11291666B2
(en)
|
2016-09-12 |
2022-04-05 |
Intra-Cellular Therapies, Inc. |
Uses
|
|
WO2019118313A1
(en)
|
2017-12-13 |
2019-06-20 |
Merck Sharp & Dohme Corp. |
Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
|
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
|
US12410175B2
(en)
|
2019-09-03 |
2025-09-09 |
Intra-Cellular Therapies, Inc. |
Compounds
|
|
CN111072676B
(zh)
*
|
2019-12-12 |
2021-07-16 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|